Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News 3 Undervalued Names Too Cheap to IgnoreBy Nathan Reiff. Date Posted: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 seem like a poor time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, featuring metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, including compelling dividends or promising new product developments. While value opportunities may be harder to find when many companies have renewed investor attention—or when apparent bargains come with deteriorating operations—well-established and stable names can still present attractive prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Are You Overpaying Your Capital Gains Tax Bill? If you've sold investments or property in the last year, you may be able to reduce capital gains taxes depending on your situation. Take this free 2-minute quiz to get matched with a fiduciary advisor in your area who may be able to help you keep more of what you've built. Take the free quiz. Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical-industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has about 5% additional upside in the near term. Helping to drive Merck's momentum is its pembrolizumab cancer drug, Keytruda, which gained approval for subcutaneous injection from the European Commission in late 2025 and generated roughly $8.4 billion in sales in Q4 2025, up almost 7% year-over-year. Keytruda also shows promise in ovarian cancer, potentially expanding its addressable patient base as Merck plans for the drug's patent expiry in 2028. Merck's portfolio is broadening: the company recently announced notable phase 3 trial results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck has restructured its human health operations into two separate units to make it easier to grow non–cancer-drug sales as it navigates Keytruda's eventual loss of exclusivity. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell’s (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple has faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest year-over-year declines in organic net sales and consumption, with adjusted EPS down 13% over the same period. Margin improvement has been slow to materialize despite cost-saving initiatives. The near term will likely remain challenging for the iconic brand, as fiscal-year guidance is weak overall. Still, Campbell's improving supply chain and strong brand loyalty—particularly for its premium offerings—should help cushion the company. Changes to tariff dynamics may also ease some of the external pressure it faces. On the income side, Campbell's remains a notable dividend play, offering a 5.9% yield, though its payout ratio is high at over 80%. Its P/E ratio of about 13.5 is the lowest it has been in roughly four years, which may attract value-oriented investors despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice-distribution leader US Foods (NYSE: USFD) has followed almost the opposite path of Campbell's—shares are up roughly 33% over the last year. Still, its P/E ratio of 31.6 can look modest relative to some peers and the broader market context. On the fundamentals, US Foods is making meaningful strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA growth of 11% year-over-year. Better inventory management and cost-of-goods improvements are helping the firm gain traction. With a $4-billion capital-deployment strategy in place, US Foods is well positioned to sustain revenue momentum and continue expanding adjusted EBITDA. Analysts rate USFD a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential. | 
